Melissa B. Epperly, Chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), sold 2,573 shares at $11.44 ($29K) on 2024-02-12, disclosed to the SEC on 2024-02-12.
Scheduled sale ($29k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ROIV | SELL | 2026-07-01 | $610K | — | Filing → |
| ROIV | SELL | 2026-03-18 | $1.2M | — | Filing → |
| ZNTL | SELL | 2024-02-05 | $200K | — | Filing → |